Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Endocrinology and Metabolic Disorders

Artivion and Endospan Agreement; Masimo and Cle...

Artivion Amended Agreements With Endospan On June 01, 2024, Artivion, Inc. a prominent company in cardiac and vascular surgery specializing in aortic disease, announced that it revised its credit f...

Jul 04, 2024

transforming-obesity-treatment
The Race to Redefine Obesity Treatment

Obesity ranks as the second leading cause of preventable death, linked to the risk of inflammatory conditions that are directly and indirectly related to cardiovascular disease, diabetes, respiratory issues, psychological problems, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. This poses a majo...

Find More
type-1-diabetes-in-ada-2024
Advances in Type 1 Diabetes (T1D) Treatment: Cutting-Edge Therapies and Innovations Unveiled at ADA 2024

Type 1 Diabetes (T1D) arises from the autoimmune destruction of insulin-producing islet cells in the pancreas. This destruction results in a complete loss of insulin production, leading to significant impairment in blood glucose control. Without insulin, the body cannot properly process nutrients, causing persisten...

Find More
emerging-therapies-for-obesity-in-ada-2024
Beyond GLP-1: Emerging Therapies for Obesity Discussed at ADA 2024

Obesity, a chronic disease linked to increased risks of complications and mortality, has spurred significant research into the mechanisms of weight regulation and the gut-brain axis's role in appetite control. This understanding has paved the way for the development of safe and effective treatments, such as glucago...

Find More

More Views & Analysis

glp-1-receptor-agonists-in-ada-2024
Next-gen GLP-1 Breakthroughs: Revolutionizing Diabetes and Obesity Treatment at ADA 2024

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity by lowering serum glucose levels and managing metabolism in affected patients. Companies are continuously striving to improve approved therapies and develop next-generation obesity ...

Find More

top-highlights-from-ada-conference-2024
Advancing Diabetes Care: Highlights from the ADA’s 84th Scientific Sessions

The American Diabetes Association (ADA), a premier voluntary health organization, has been at the forefront of combating the diabetes epidemic and enhancing the lives of individuals with diabetes for 83 years. The ADA has consistently fueled discovery and research aimed at treating, managing, and preventing diabete...

Find More

pharma-news-for-alnylam-bms-daichii-sankyo-vertex
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...

Find More

pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval

Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...

Find More

pharma-news-for-moderna-almirall-lilly-ipsen
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval

Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...

Find More

rezdiffra-journey-in-nash-treatment
Empowering Change: REZDIFFRA’s Trailblazing Journey in NASH Treatment

Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll o...

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

Today, Artificial Intelligence has been used effectively in data processing, drug discovery, aiding .....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

Multiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....

Find More

Nestlé and Unilever are multinational corporations established in 1866 and 1930, respectively. The .....

Find More

The medical device industry is experiencing rapid change as innovation is accelerating, new business.....

Find More